It’s been a crucial week for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN); here’s what analysts have to say.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) LogoInvestors sentiment increased to 1.21 in Q2 2018. Its up 0.25, from 0.96 in 2018Q1. It increased, as 30 investors sold BioMarin Pharmaceutical Inc. shares while 118 reduced holdings. 57 funds opened positions while 122 raised stakes. 177.65 million shares or 1.83% more from 174.46 million shares in 2018Q1 were reported.
The Pennsylvania-based Pnc Group Inc has invested 0% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Jabre Cap reported 30,000 shares or 0.19% of all its holdings. Sands Cap Ltd Liability accumulated 1.87% or 6.93M shares. Livforsakringsbolaget Skandia Omsesidigt owns 3,520 shares. Lord Abbett And Limited Liability, New Jersey-based fund reported 110,376 shares. Alyeska Investment Lp holds 557,701 shares. Clearbridge Invs Limited Liability has invested 0.28% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Alliancebernstein L P holds 0.01% or 108,368 shares in its portfolio. Kbc Group Nv accumulated 0.03% or 41,194 shares. Morgan Stanley holds 587,176 shares or 0.01% of its portfolio. Hanson Doremus Management reported 200 shares. 125,000 are held by Eulav Asset. Uss Investment Ltd, United Kingdom-based fund reported 1.11 million shares. New York State Common Retirement Fund accumulated 475,415 shares. Reilly Advsrs Limited Liability Company owns 0.04% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 2,700 shares.

Since June 11, 2018, it had 0 insider buys, and 23 insider sales for $13.07 million activity. $1.19 million worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) was sold by Davis George Eric on Thursday, September 13. On Tuesday, August 28 the insider LEWIS ALAN sold $743,327. Ajer Jeffrey Robert sold $129,685 worth of stock. $687,954 worth of stock was sold by BAFFI ROBERT on Friday, June 22. The insider MEIER RICHARD A sold $297,722. Mueller Brian also sold $312,928 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Ratings Coverage

Among 9 analysts covering BioMarin (NASDAQ:BMRN), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. BioMarin had 12 analyst reports since June 15, 2018 according to SRatingsIntel. The rating was maintained by Wedbush on Friday, June 15 with “Buy”. The rating was maintained by Stifel Nicolaus on Friday, August 3 with “Buy”. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) earned “Outperform” rating by Wedbush on Monday, August 6. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) earned “Overweight” rating by Morgan Stanley on Friday, August 3. Citigroup maintained the stock with “Buy” rating in Thursday, August 9 report. The stock has “Buy” rating by Canaccord Genuity on Tuesday, July 31. Raymond James maintained it with “Outperform” rating and $114 target in Friday, October 26 report. Barclays Capital maintained the stock with “Equal-Weight” rating in Monday, August 6 report. On Tuesday, October 23 the stock rating was maintained by Canaccord Genuity with “Buy”. The rating was maintained by Credit Suisse with “Outperform” on Monday, July 9. Below is a list of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) latest ratings and price target changes.

28/11/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $126.0000 Maintain
26/10/2018 Broker: Raymond James Old Rating: Outperform New Rating: Outperform Old Target: $113 New Target: $114 Maintain
23/10/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $113 New Target: $116 Maintain
01/10/2018 Broker: Cantor Fitzgerald Rating: Overweight New Target: $126 Initiates Coverage On
09/08/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $108 New Target: $120 Maintain
06/08/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $95 New Target: $98 Maintain
06/08/2018 Broker: Wedbush Old Rating: Outperform New Rating: Outperform Old Target: $115 New Target: $120 Maintain
03/08/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $102 New Target: $109 Maintain
03/08/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $113 New Target: $115 Maintain
31/07/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $105 New Target: $113 Maintain

The stock increased 1.97% or $1.85 during the last trading session, reaching $95.54. About 1.09M shares traded. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has risen 7.26% since December 7, 2017 and is uptrending. It has underperformed by 8.36% the S&P500.

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. The company has market cap of $17.01 billion. The Company’s commercial products include Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria , an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. It currently has negative earnings. The firm also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis, a form of Batten disease; pegvaliase, an enzyme substitution therapy for the treatment of PKU; vosoritide, a peptide therapeutic for the treatment of achondroplasia; BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate, for the treatment of hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase for the treatment of Sanfilippo B syndrome, or mucopolysaccharidosis type IIIB.

More notable recent BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) news were published by: Streetinsider.com which released: “Baker Bros. Advisors 13F for Quarter Ended Sept. 30, 2018 – StreetInsider.com” on November 14, 2018, also Seekingalpha.com with their article: “BioMarin: Gene Therapy Pipeline Driving Valuation Upside – Seeking Alpha” published on August 09, 2018, Nasdaq.com published: “Nasdaq 100 Movers: ADBE, BMRN – Nasdaq” on June 15, 2018. More interesting news about BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) were released by: Nasdaq.com and their article: “3 Biotech Stocks With Virtual Monopolies – Nasdaq” published on October 03, 2018 as well as Nasdaq.com‘s news article titled: “Catalysts That Could Move Catalyst Pharma – Nasdaq” with publication date: November 28, 2018.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.